drugset / Trial / NCT01821560
Baclofen Effects in Cigarette Smokers
Phase 2
Completed
44 enrolled
University of Pennsylvania
National Institute on Drug Abuse (NIDA) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The proposed project will utilize perfusion functional magnetic resonance imaging (fMRI), a functional candidate gene association approach (of dopaminergic addictions-targeted polymorphisms), and the dopamine-modulating and gamma-aminobutyric acid (GABA) B receptor agonist, baclofen, to examine the brain and behavioral responses in smokers to appetitive smoking reminders (cues that motivate continued smoking and relapse). These studies will provide a means to identify an appetitive cue-sensitive pharmacologic-responsive endophenotype. Once brain/behavioral/genetic endophenotypes can be determined prior to treatment, smoking cessation treatments can be structured to meet individual needs, which will significantly improve treatment outcome.
Timeline
- Start
- 2013-03
- Primary completion
- 2017-06
- Completion
- 2017-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Baclofen | Small molecule | 20 mg | Oral |